How Does At-Home Skyrizi Induction Change GI Billing?
At-home Skyrizi induction is an FDA-approved subcutaneous regimen that lets adults with Crohn’s disease start risankizumab with an on-body injector instead of three IV infusions. As of October 2026, induction can move from the practice’s medical-benefit claims under J2327 to the patient’s pharmacy benefit, which shifts prior authorization, infusion chair revenue, and buy-and-bill inventory for GI practices.
What changed: On October 23, 2026, the FDA approved 720 mg subcutaneous induction at weeks 0, 2, 4, and 8 for Crohn’s disease.
What stays the same: The 600 mg IV induction option remains, and the approval does not change ulcerative colitis induction.
What to do now: Flag new Crohn’s starts, confirm which benefit covers induction, and update prior authorization workflows.
What the FDA Approved on October 23, 2026
AbbVie announced on October 23, 2026 that the FDA approved a subcutaneous induction regimen for Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn’s disease. Patients receive 720 mg through an on-body injector induction pack at weeks 0, 2, 4, and 8, then continue maintenance with the same device every eight weeks starting at week 12.
The intravenous option, 600 mg at weeks 0, 4, and 8, remains available. What changed is that a patient can now go from first dose to maintenance without a single infusion visit. The on-body injector itself is not new; it has been used for Crohn’s maintenance since 2022.
The approval rests on the phase 3 AFFIRM trial of 274 adults, 65% of whom had already failed at least one advanced therapy. As AJMC reported, 56% of patients on subcutaneous risankizumab reached clinical remission at week 12 versus 30% on placebo, and 43% achieved endoscopic response versus 15%. The FDA also updated the label across all indications so clinicians can use judgment on whether tuberculosis testing is needed before treatment.
Here is how the two induction routes compare for billing:
| Billing factor | IV induction | Subcutaneous induction |
| Dose and schedule | 600 mg at weeks 0, 4, and 8 | 720 mg at weeks 0, 2, 4, and 8 |
| Where it happens | Infusion suite or center | Patient’s home |
| Benefit that usually pays | Medical benefit | Pharmacy benefit |
| What the practice bills | J2327 drug units plus 96365 administration | Visits and services, not the drug |
| Medicare coverage path | Part B | Part D, as a self-administered drug |
Which GI Practices Does This Affect Most?
GI practices with in-office infusion suites or owned infusion centers feel this change most, because Skyrizi induction for Crohn’s disease can now leave their chairs entirely. Practices that refer infusions out see a smaller shift, mostly in prior authorization paperwork, since the pharmacy benefit replaces the medical benefit for patients who start at home.
IBD-focused groups carry the most volume. A practice that starts several new Crohn’s patients on Skyrizi each quarter has been billing three induction infusions per patient under J2327, each with its own administration code, prior authorization, and drug inventory. Every patient who chooses home induction removes all three from the infusion schedule.
Payer mix matters too. For Medicare patients, a drug the patient gives themselves generally falls outside Part B under the self-administered drug exclusion in the Medicare Benefit Policy Manual, Chapter 15, Section 50.2, so home induction runs through Part D. Commercial patients typically fill it through a specialty pharmacy.
Hospital-based practices face a slightly different version of the same shift. When infusions run through a hospital outpatient department, the facility bills the drug and a facility fee, so home induction moves revenue out of the hospital’s ledger as well as the physician’s. The physician side keeps evaluation visits and monitoring either way.
Not every patient will switch. Some will prefer supervised infusions, some plans may cover one route more favorably than the other, and ulcerative colitis patients still start Skyrizi under the existing intravenous regimen because this approval covers Crohn’s disease only. Practices will run both workflows side by side for the foreseeable future.
Why Biologic Induction Is Moving Home
One question we hear constantly from GI practice managers is whether infusion suites are still worth the space. This approval sharpens that question, because induction was one of the last phases of IBD therapy that reliably required a chair.
The pattern has been building for years. Vedolizumab and infliximab already have subcutaneous versions used for maintenance, and Skyrizi’s on-body injector has handled Crohn’s maintenance since 2022. Moving induction to the same device completes the shift for this drug: the patient never has to sit for an infusion unless they or their physician choose to.
Patients have signaled they want it. AbbVie cited a real-world survey in which 88% of 186 adults with Crohn’s disease said the on-body injector was easy to use, and infusion visits carry travel and time away from work.
Payers have their own reasons to watch. Infusion services billed under the medical benefit include administration fees and, in hospital settings, facility charges, while a self-administered drug avoids both. As of October 2026, no major payer has announced a policy requiring home induction for Skyrizi, but some plans already apply site-of-care reviews to intravenous biologics.
The signal for GI practices is that infusion revenue should be planned drug by drug rather than assumed. Each new subcutaneous option changes the math for the chairs, the staff, and the inventory behind them. For practice owners weighing capital decisions, that means modeling chair utilization by drug, not by total infusion volume, before adding or cutting infusion capacity in 2027. Staffing plans should follow the same model.
What Does the Shift Mean for Infusion Revenue?
For each Crohn’s patient who chooses home induction, the practice stops billing three IV doses of Skyrizi and three infusion administrations. Most of the drug payment only offsets what the practice paid for the vials, so the real revenue at stake is the add-on Medicare pays above the drug’s average sales price, plus the administration fees.
The numbers are large. Under the CMS October 2026 Part B payment limit file, J2327 pays $14.011 per milligram, so one 600 mg induction dose is $8,406.60 and the three-dose IV course is $25,219.80. Infusion code 96365 adds $67.14 per visit at the 2026 national office rate, or $201.42 for the course, for a total allowed amount of about $25,421.22.
Medicare sets most Part B drug payments at 106% of average sales price. The 6% add-on in the Skyrizi course is roughly $1,427.54, and with administration fees the practice’s margin exposure is about $1,628.96 per patient before sequestration and acquisition discounts. If 10 Crohn’s patients a year choose home induction, that is about $16,290 in add-on and administration revenue the infusion suite no longer collects.
The freed chairs are the other half of the equation. Ten patients represent 30 infusion slots a year that can go to other biologics. A 300 mg vedolizumab dose under J3380, for example, carries a payment limit of $6,284.70 in the same CMS file.
Timing matters as well. Buy-and-bill practices pay for vials before they are reimbursed, so fewer Skyrizi infusions also means less cash tied up in inventory and less exposure to denied drug claims, which can run more than $8,000 per dose.
How to Prepare Your GI Practice Now
Work through these seven steps before your next Crohn’s patient starts Skyrizi:
- List every patient in or near Skyrizi induction. Note the route, the induction week, and the date maintenance begins at week 12.
- Run benefits checks for both routes. Confirm whether the medical benefit, the pharmacy benefit, or both will cover induction before the order goes out.
- Update prior authorization templates. Build a pharmacy-benefit request for home induction alongside the existing medical-benefit request for J2327.
- Keep IV claims precise. Bill J2327 in 1 mg units, 600 units per Crohn’s induction infusion, with the JZ modifier when the full single-dose vial is used.
- Re-plan chair time and inventory. Reduce standing Skyrizi vial orders and fill open slots with infusions that still require a chair.
- Document tuberculosis testing decisions. Record whether testing was performed under the updated label, since some payer criteria may still ask for it.
- Track the week-12 handoff. Make sure maintenance prescriptions move to the pharmacy benefit on schedule so therapy does not lapse.
Each step protects revenue in a different place. Benefits checks prevent denied infusions, clean J2327 claims prevent recoupments, and inventory changes keep capital from sitting in a refrigerator. Revisit the list monthly as new patients start and existing patients reach maintenance, and assign one owner so nothing falls between the front desk and the infusion nurses.
Across the billing companies we vet, the ones that handle GI infusion well already treat each biologic as its own workflow, with separate authorization tracking, unit checks, and modifier rules for every drug on the infusion schedule.
Need a billing partner that already manages biologic authorizations and infusion claims? We’ll match your GI practice with a vetted billing company in as little as 30 minutes, with rates starting as low as 2.95%.
Common Billing Mistakes During the Transition
These are the errors most likely to cost GI practices money as patients split between routes.
Billing J2327 for subcutaneous doses. J2327 describes intravenous risankizumab. Home doses filled through a pharmacy are not billed by the practice as a drug.
Using the wrong authorization path. An approval for IV induction under the medical benefit does not cover home induction under the pharmacy benefit, and the reverse is also true.
Billing administration for home doses. Infusion administration codes such as 96365 apply only when the practice actually administers an infusion.
Dropping the JZ modifier. Medicare requires JW or JZ on claims for single-dose containers, and the Skyrizi IV dose for Crohn’s uses a full 600 mg vial.
Assuming every patient switched. Some patients will stay on IV induction, so schedules and authorizations need to reflect each patient’s actual route.
Losing track of documentation. Payers continue to ask for disease activity and response documentation at reauthorization, whichever route the patient used.
Forgetting ulcerative colitis rules. The new subcutaneous induction applies to Crohn’s disease only, so ulcerative colitis claims should follow the existing intravenous induction regimen on the label.
Missing the NDC on drug claims. Many payers require the 11-digit NDC, 00074-5015-01 for the Skyrizi IV vial, alongside J2327 on drug lines.
Each of these is easy to catch before submission and expensive to fix after a denial or audit. Building route-specific checks into charge review now keeps the transition from turning into months of rework, and keeps cash flow steady while patients move between routes.
In-House Billing vs. a GI Billing Partner
Providers often come to us after an infusion program grows faster than their billing team, and drug authorizations, unit counts, and modifier rules start slipping through the cracks.
Gastroenterology Billing is a free matching platform powered by Billing Service Quotes, whose network has matched more than 2,000 providers across 60+ specialties since launching in 2024. A person reviews every request, factoring in practice size, procedure volume, payer mix, EHR system, and whether the practice runs an ambulatory endoscopy center or bills biologic infusions. Tim Daniels, Director of Strategic Accounts, speaks with every provider who comes through the platform.
Matched billing companies have experience with biologic infusion prior authorization and GI accounts receivable management, and many work inside the systems GI practices already use, including gGastro, Provation, Epic, athenahealth, eClinicalWorks, AdvancedMD, and Tebra. Many also offer credentialing and contracting support. From submission to first connection takes as little as 30 minutes.
If you are also planning for next year’s fee schedule, review our breakdown of 2027 Medicare GI payment changes, or learn more about Gastroenterology Billing and how the matching works.
When you compare partners, ask how they track authorizations by drug and route, how they reconcile J2327 units against the infusion record, and how quickly they work drug denials, since a single denied dose can exceed $8,000. Billing Service Quotes is compensated by the billing companies in its network, so matching is free for practices, with no obligation to move forward with any company introduced. You can also reach the team at (844) 863-5233.
Frequently Asked Questions
What is the new Skyrizi subcutaneous induction dose for Crohn’s disease?
The approved subcutaneous induction is 720 mg delivered by an on-body injector at weeks 0, 2, 4, and 8. Maintenance continues with the injector every eight weeks starting at week 12. The intravenous option of 600 mg at weeks 0, 4, and 8 remains available.
Is at-home Skyrizi induction billed under the medical or pharmacy benefit?
Home induction is usually covered under the pharmacy benefit because the patient self-administers it. Medicare Part B generally excludes self-administered drugs, so Medicare patients typically use Part D. Coverage varies by plan, so practices should verify each patient’s benefits before ordering.
What HCPCS code is used for IV Skyrizi?
Intravenous risankizumab is billed with J2327 in 1 mg units, so a 600 mg Crohn’s induction dose is 600 units. Under the CMS October 2026 payment limit file, J2327 pays $14.011 per unit, and the JZ modifier applies when the full single-dose vial is used.
Does the approval change ulcerative colitis billing?
No. The October 2026 approval covers subcutaneous induction for Crohn’s disease only. Ulcerative colitis patients still start Skyrizi under the existing intravenous induction regimen, so practices should continue billing those infusions with J2327 and the appropriate administration codes for each dose.
Do patients still need tuberculosis testing before starting Skyrizi?
The updated label lets clinicians use judgment on whether tuberculosis testing is needed, rather than requiring it. Some payers may still list testing in their authorization criteria, so practices should document the clinical decision and check each plan’s requirements before submitting.
Will payers require at-home induction instead of IV infusions?
As of October 2026, no major payer has announced a requirement for home induction of Skyrizi. Some plans already review the site of care for intravenous biologics, so practices should watch payer policy bulletins and site-of-care updates in the months ahead.
Next Steps
- Plan for next year with our 2027 Medicare GI payment changes breakdown.
- See how matching works on the Gastroenterology Billing homepage.
- Learn more about Gastroenterology Billing and the team behind it.
Get matched with a GI billing partner that handles biologic infusions, prior authorizations, and endoscopy claims, with rates starting as low as 2.95%.
